The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia
{{output}}
Chimeric antigen receptor (CAR) T cells have demonstrated remarkable ability to render multiple relapsed and refractory patients into a deep and often durable remission. Since initial FDA approval of tisagenlecleucel in 2017, real-world data have shown the ben... ...
